KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.

Jorge E Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A Larson, Ghayas C Issa, Felice Bombaci, Nicholas Ramscar, Sophie Ifrah, Timothy P Hughes

Future Oncol 18(38) 4161-4170

PMID36524980
PMCID-
DOI10.2217/fon-2022-0923
发表日期2022-12-16
摘要

摘要

Asciminib is the first BCR::ABL1 inhibitor that works by Specifically Targeting the ABL Myristoyl Pocket (STAMP). Asciminib has shown favorable efficacy and safety in patients with chronic myeloid leukemia in chronic phase without the T315I mutation who have received ≥2 prior tyrosine kinase inhibitors (TKIs) in phase I and III clinical trials and in patients with the T315I mutation who have received ≥1 prior TKI in phase I. ASC4FIRST (NCT04971226) is a phase III, multicenter, open-label, randomized study of asciminib versus investigator-selected TKI in patients with newly diagnosed chronic myeloid leukemia in chronic phase. The primary end point is major molecular response at week 48. Secondary end points include responses at and by scheduled time points, safety, pharmacokinetics and patient-reported outcomes. Clinical Trial Registration: NCT04971226 (ClinicalTrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。